Skip to main content

Table 4 Literature review of studies on the efficacy of IFN-free regimens in hereditary bleeding disorder patients with HCV infection

From: Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders

Author Study date Study location Sample size, n Anti-HCV regimen, % HCV genotype, % Treatment naïve, % HIV co-infection, % Cirrhosis, % SVR
Fransen et al. [29] 2019 Belgium 85 SOF/LDV: 2.4% NA* 72.6 NA* 12 77/84 (91.6%)
SOF/VEL: 16.4%
SOF + SIM: 5.9%
SOF + DCV: 12.9%
OBV/r/PTV ± DSV: 20.0%
EBR/GZR: 21.2%
GLE/PIB: 12.9%
Others**: 8.2%
Walsh et al. [3] 2017 US 120 SOF/LDV: 86.7% 1: 0.8% 60 21.7% 30.8 118/120 (98.3%)
SOF + RBV: 13.3% 1a: 59.2%
1b: 25.9%
2: 8.3%
3: 5%
4: 0.8%
Nagao et al. [31] 2017 Japan 43 SOF/LDV: 100% 1a: 58.1% 58.1 46.5% 20.9 41/43 (95.3%)
1b: 27.9%
1a + 2b: 2.3%
4: 11.7%
Lee et al. [7] 2017 Korea 30 DCV + ASV: 60% 1b: 70% 70 NR 13.3 28/30 (93.3%)
LDV/SOF: 26.7% 1a: 16.7%
SOF + RBV: 13.3% 2a/2b: 13.3%
Stedman et al. [32] 2016 New Zealand 14 SOF/LDV + RBV: 100% 1a: 71% 79 0% 7 14/14 (100%)
1b: 29%
Mancuso et al. [17] 2020 Italy 200 SOF/VEL: 22.5% 1a: 63% 54 20% 28 198/200 (99%)
GLE/PIB: 20% 1b: 15%
SOF/LDV: 11.5% 1: 1%
SOF/LDV + RBV: 10% 2: 12%
SOF + SIM: 6.5% 3: 7%
GZR/EBR: 6.5% 4: 3%
DSV/PTV/OBV/r: 5.5%
DSV/PTV/OBV/r + RBV: 5%
SOF + DCV + RBV: 4%
DCV + RBV: 2.5%
SOF + DCV: 2%
SOF + RBV: 1.5%
SOF/VEL + RBV: 1.5%
SOF + SIM + RBV: 1%
Xiao et al. [34] 2019 China 12 SOF + DCV: 66.7% 1b: 75% 41.7 100% 33 12/12 (100%)
SOF/VEL: 16.7% 2i: 16.7%
SOF + RBV: 8.3% 3: 8.3%
DCV + ASV: 8.3%  
Uemura et al. [33] 2017 Japan 27 SOF/LDV: 85.2% 1a: 15% 33 100% 41 27/27 (100%)
SOF + RBV: 3.7% 1b: 59%
SOF + DCV: 11.1% 1: 7%
2a: 4%
3a: 11%
4a: 4%
Guedes et al. [30] 2020 Portugal 16 SOF/LDV: 75% 1a: 40% 12.5 NR 62.5 16/16 (100%)
SOF/LDV + RBV: 6.25% 1b:46.6%
SOF + RBV: 6.25% 2: 6.7%
OBV/PTV/r + DSV: 6.25% 3a: 6.7%
EBR/GZR: 6.25%
Current study 2020 Iran 147 SOF/LDV: 27.9% 1: 68.1% 46.3 4.1% 25.2 132/132 (100%)
SOF/LDV + RBV: 36.1% 2: 1.4%
SOF/DCV: 17.7% 3: 20.8%
SOF/DCV + RBV: 12.2% 4: 2.8%
SOF/VEL: 5.4% Mix: 6.9%
SOF + RBV: 0.7%
  1. NR not reported, NA not available, DSV dasabuvir, EBR elbasvir, GLE glecaprevir, GZR grazoprevir, LDV ledipasvir, OBV ombitasvir, VEL velpatasvir, VOX voxilaprevir, DCV daclatasvir, ASV asunaprevir, SIM simprevir, PTV paritaprevir, PIB pibrenastavir, r ritonavir, SVR sustained virologic response, HIV human immunodeficiency virus
  2. *The HCV genotyping and HIV co-infection data were reported for total cases, not patients who received DAAs
  3. **Not mentioned in the article